Literature DB >> 29637628

PKCα in colon cancer cells promotes M1 macrophage polarization via MKK3/6-P38 MAPK pathway.

Yang Cheng1,2, Yun Zhu3, Wanfu Xu1,2, Jiajia Xu1,2, Min Yang1, Peiyu Chen1, Junhong Zhao1, Lanlan Geng1, Sitang Gong1.   

Abstract

Tumor associated macrophages are potential targets of the immune therapy for patients with colon cancer. PKCα acts as a tumor suppressor in the intestine. However, the correlation between PKCα expressed in colon cancer cells and tumor associated macrophages polarization has never been detected. In the present study, the correlation between PKCα expression and level of M1 macrophages was evaluated in human colon cancer tissues. A xenograft mouse model of colon cancer cells with different PKCα expression level was constructed to evaluate the effect of PKCα on M1 macrophages polarization in vivo. Co-culture of colon cancer cells and differentiated macrophages was used to detect the potential interplay in vitro. PKCα regulated production of cytokines which correlated with macrophage polarization and the underlying mechanism was further explored. Our study showed that high PKCα expression in human colon cancer tissues correlated with better prognosis and high M1 macrophage content. PKCα expressed in colon cancer cells inhibited the growth of colon cancer in mice model. PKCα induced macrophages polarized to the M1-like phenotype both in vitro and in vivo. Mechanistically, PKCα targeted P38 via MKK3/6 to promote IL12 and GM-CSF expression which further enhanced M1-like macrophages polarization. In conclusion, this study provided evidence for the first time that PKCα in colon cancer cells play an anticancer action by inducing the polarization of tumor associated macrophages to M1-like phenotype in the tumor microenvironment. PKCα promoted IL12/GM-CSF-mediated M1 polarization through MKK3/6-P38 signaling pathway. Our investigation suggested that modulation of the PKCα signaling pathway might serve as a novel strategy for colon cancer therapy.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  GM-CSF; IL12; P38; PKCα; colon cancer; macrophage polarization

Mesh:

Substances:

Year:  2018        PMID: 29637628     DOI: 10.1002/mc.22822

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

Review 1.  Exosomal non-coding RNAs: Emerging roles in bilateral communication between cancer cells and macrophages.

Authors:  Wenhao Li; Xiaolong Wang; Chen Li; Tong Chen; Qifeng Yang
Journal:  Mol Ther       Date:  2021-12-02       Impact factor: 11.454

2.  Baicalin Suppresses Bilirubin-Induced Apoptosis and Inflammation by Regulating p38 Mitogen-Activated Protein Kinases (MAPK) Signaling in Neonatal Neurons.

Authors:  Shuang Shi; Qianwei Cui; Jing Xu; Zhiguo Tang; Binya Shi; Zhongwei Liu
Journal:  Med Sci Monit       Date:  2020-07-07

3.  Production of NOS2 and inflammatory cytokines is reduced by selected protein kinase inhibitors with partial repolarization of HL-60 derived and human blood macrophages.

Authors:  Gábor Bögel; József Murányi; Bálint Szokol; Zoltán Kukor; István Móra; Tamás Kardon; László Őrfi; András Hrabák
Journal:  Heliyon       Date:  2021-12-27

Review 4.  Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses.

Authors:  Jun Li; Dawei Chen; Minhong Shen
Journal:  Front Med (Lausanne)       Date:  2022-03-23

5.  Pleiotropic ZIP8 A391T implicates abnormal manganese homeostasis in complex human disease.

Authors:  Laxmi Sunuwar; Azra Frkatović; Sodbo Sharapov; Qinchuan Wang; Heather M Neu; Xinqun Wu; Talin Haritunians; Fengyi Wan; Sarah Michel; Shaoguang Wu; Mark Donowitz; Dermot McGovern; Gordan Lauc; Cynthia Sears; Joanna Melia
Journal:  JCI Insight       Date:  2020-10-15

6.  p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition.

Authors:  Daniel Baumann; Jennifer Drebant; Tanja Hägele; Luisa Burger; Clara Serger; Claudia Lauenstein; Przemyslaw Dudys; Gerrit Erdmann; Rienk Offringa
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.